1 hr ago
Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk
Takeda Pharmaceuticals and Eli Lilly & Co lost a bid to overthrow a combined $9 billion punitive-damage award by a U.S. jury for hiding cancer risks associated with their Actos diabetes drug, according to a court ruling.
5 hrs ago
Takeda, Lilly Lose Bid to Get $9 Billion Actos Award Thrown Out
Takeda Pharmaceutical Co. and Eli Lilly & Co. lost a bid to have a judge throw out a combined $9 billion punitive damage award over claims the drugmakers hid the cancer risks of their Actos diabetes medicine.
10 hrs ago
Takeda Announces Completion of the Post-Marketing Commitment to...
In the five-year interim analysis published in Diabetes Care , a statistically significant increased risk among patients who used pioglitazone for two or more years was observed.1 However, the 10-year final analysis did not show any statistically significant findings of increased risk of bladder cancer with long term use of pioglitazone.2 The data ... (more)
Thiazolidinedione therapy versus lifestyle recommendation in the...
Background Few studies have investigated intervention therapy to reduce steatosis in the liver allograft post-transplantation.
Targeting renal glucose reabsorption for the treatment of type 2...
Sodium-glucose co-transporter 2 plays a key role in glucose homeostasis as the key transporter responsible for most renal glucose reabsorption in the proximal tubules of the kidney.
Ema CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync
Takeda Pharmaceuticals International GmbH today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics for VipidiaTM and the fixed-dose combination therapies VipdometTM and IncresyncTM .